Development
ADMA Biologics, Inc.
ADMA
$18.96
-$0.95-4.77%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -17.64M | 2.57M | -6.37M | -6.79M | -12.23M |
| Total Depreciation and Amortization | 2.10M | 2.09M | 2.10M | 2.03M | 1.94M |
| Total Amortization of Deferred Charges | 707.20K | 721.00K | 686.90K | 487.90K | 493.90K |
| Total Other Non-Cash Items | 28.83M | 2.74M | 2.59M | 2.07M | 2.43M |
| Change in Net Operating Assets | 3.60M | 3.86M | -5.06M | -12.53M | -3.60K |
| Cash from Operations | 17.60M | 11.99M | -6.06M | -14.72M | -7.38M |
| Capital Expenditure | -1.20M | -756.60K | -872.60K | -1.94M | -3.75M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -210.00K | -- | -- | -- | -- |
| Cash from Investing | -1.41M | -756.60K | -872.60K | -1.94M | -3.75M |
| Total Debt Issued | 135.00M | -- | -- | -- | 0.00 |
| Total Debt Repaid | -158.59M | 0.00 | -6.50K | -9.60K | -8.70K |
| Issuance of Common Stock | 8.50K | 624.00K | 471.50K | -- | 64.82M |
| Repurchase of Common Stock | -340.50K | -208.60K | -225.00K | -640.90K | -2.07M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -15.08M | -- | -- | -- | -100.00 |
| Cash from Financing | -38.99M | 415.40K | 240.10K | -650.50K | 62.74M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -22.81M | 11.64M | -6.69M | -17.32M | 51.62M |